Antimicrobial stewardship: Another focus for patient safety?

Current Opinion in Infectious Diseases

Volumn 27, Issue 4, 2014, Pages 348-355

  Tamma, Pranita D ^a   Holmes, Alison ^b   Ashley, Elizabeth Dodds ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Antibiotics; Antimicrobial resistance; Antimicrobial stewardship; Safety

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; HUMAN; PATIENT SAFETY;

ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MICROBIAL; HUMANS; PATIENT SAFETY;

EID: 84905818848     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000077     Document Type: Review

References (73)

1. Tamma PD, Cosgrove SE. Antimicrobial stewardship. Infect Dis Clin North Am 2011; 25:245-260.
2. Valiquette L, Cossette B, Garant MP, et al. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficileassociated disease caused by the hypervirulent NAP1/027 strain. Clin Infect DisV 45 2007; (Suppl 2):S112-S121.
3. Malani AN, Richards PG, Kapila S, et al. Clinical and economic outcomes from a community hospital's antimicrobial stewardship program. Am J Infect Control 2013; 41:145-148.
4. Dancer SJ, Kirkpatrick P, Corcoran DS, et al. Approaching zero: temporal effects of a restrictive antibiotic policy on hospital-Acquired Clostridium difficile, extended-spectrum beta-lactamase-producing coliforms and meticillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 2013; 41:137-142.
5. Debast SB, Vaessen N, Choudry A, et al. Successful combat of an outbreak due to Clostridium difficile PCR ribotype 027 and recognition of specific risk factors. Clin Microbiol Infect 2009; 15:427-434.
6. Aldeyab MA, Kearney MP, Scott MG, et al. An evaluation of the impact of antibiotic stewardship on reducing the use of high-risk antibiotics and its effect on the incidence of Clostridium difficile infection in hospital settings. J Antimicrob Chemother 2012; 67:2988-2996.
7. Pear SM, Williamson TH, Bettin KM, et al. Decrease in nosocomial Clostridium difficile-Associated diarrhea by restricting clindamycin use. Ann Intern Med 1994; 120:272-277.
8. Climo MW, Israel DS, Wong ES, et al. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-Associated diarrhea and cost. Ann Intern Med 1998; 128 (12 Pt 1):989-995.
9. Singh N, Rogers P, AtwoodCW, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care MedV 162 2000; (2 Pt 1):505-511.
10. Tamma PD, Turnbull AE, Milstone AM, et al. Ventilator-Associated tracheitis in children: does antibiotic duration matter? Clin Infect Dis 2011; 52:1324-1331.
11. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-Associated pneumonia in adults: a randomized trial. JAMA 2003; 290:2588-2598.
12. Coleman RW, Rodondi LC, Kaubisch S, et al. Cost-effectiveness of prospective and continuous parenteral antibiotic control: experience at the Palo Alto Veterans Affairs Medical Center from 1987 to 1989. Am J Med 1991; 90:439-444.
13. Recco RA, Gladstone JL, Friedman SA, Gerken EH. Antibiotic control in a municipal hospital. JAMA 1979; 241:2283-2286.
14. White AC Jr, Atmar RL, Wilson J, et al. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997; 25:230-239.
15. Ozkurt Z, Erol S, Kadanali A, et al. Changes in antibiotic use, cost and consumption after an antibiotic restriction policy applied by infectious disease specialists. Jpn J Infect Dis 2005; 58:338-343.
16. Sick AC, Lehmann CU, Tamma PD, et al. Sustained savings from a longitudinal cost analysis of an internet-based preapproval antimicrobial stewardship program. Infect Control Hosp Epidemiol 2013; 34:573-580.
17. Moleski RJ, Andriole VT. Role of the infectious disease specialist in containing costs of antibiotics in the hospital. Rev Infect Dis 1986; 8:488-493.
18. Seligman SJ. Reduction in antibiotic costs by restricting use of an oral cephalosporin. Am J Med 1981; 71:941-944.
19. Woodward RS, Medoff G, Smith MD, Gray JL 3rd. Antibiotic cost savings from formulary restrictions and physician monitoring in a medical- schoolaffiliated hospital. Am J Med 1987; 83:817-823.
20. Burke JP. Infection control-A problem for patient safety. N Engl J Med 2003; 348:651-656.
21. Bond CA, Raehl CL. Clinical and economic outcomes of pharmacist-managed antimicrobial prophylaxis in surgical patients. Am J Health Syst Pharm 2007; 64:1935-1942.
22. Hecker MT, Aron DC, Patel NP, et al. Unnecessary use of antimicrobials in hospitalized patients: current patterns of misuse with an emphasis on the antianaerobic spectrum of activity. Arch Intern Med 2003; 163:972-978.
23. Trick WE, Scheckler WE, Tokars JI, et al. Modifiable risk factors associated with deep sternal site infection after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2000; 119:108-114.
24. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44:159-177.
25. Murray E, Holmes A. Addressing healthcare-Associated infections and antimicrobial resistance from an organizational perspective: progress and challenges. J Antimicrob ChemotherV 67 2012; (Suppl 1):i29-i36.
26. Charani E, Holmes AH. Antimicrobial stewardship programmes: the need for wider engagement. BMJ Qual Saf 2013; 22:885-887.
27. Barlam TF, DiVall M. Antibiotic-stewardship practices at top academic centers throughout the United States and at hospitals throughout Massachusetts. Infect Control Hosp Epidemiol 2006; 27:695-703.
28. Henriksen K, Battles JB, Keyes MA, Grady ML, editors (August 2008). Advances in patient safety: new directions and alternative approaches. Vol4Technology and medication safety. AHRQ Publication No. 08-0034-4. Rockville, MD: Agency for Healthcare Research and Quality.
29. Fridkin S, Baggs J, Fagan R, et al. Vital signs: improving antibiotic use among hospitalized patients. MMWR Morb Mortal Wkly Rep 2014; 63:194-200.
30. Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-Associated adverse events. Clin Infect Dis 2008; 47: 735-743.
31. Polk RE, Fox C, Mahoney A, et al. Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clin Infect Dis 2007; 44:664-670.
32. Abbo LM, Cosgrove SE, Pottinger PS, et al. Medical students' perceptions and knowledge about antimicrobial stewardship: how are we educating our future prescribers? Clin Infect Dis 2013; 57:631-638.
33. McGlynn EA, Asch SM, Adams J, et al. The quality of healthcare delivered to adults in the United States. N Engl J Med 2003; 348:2635-2645.
34. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-455.
35. Chary A, Tice AD, Martinelli LP, et al. Experience of infectious diseases consultants with outpatient parenteral antimicrobial therapy: results of an emerging infections network survey. Clin Infect Dis 2006; 43:1290-1295.
36. Winters RW, Parver AK, Sansbury JD. Home infusion therapy: a service and demographic profile. A report for the National Alliance for Infusion Therapy. Washington DC: National Alliance for Infusion Therapy; 1992.
37. Winters RW. Home infusion therapy industry: an overview. In: Conners RB, Winters RW, editors. Home Infusion therapy: current status and future trends. American Hospital Publishing Inc; 1995. pp. 1-15.
38. Surawicz CM, Brandt LJ, Binion DG, et al.Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108:478-498; quiz 499.
39. Jumani K, Advani S, Reich NG, et al. Risk factors for peripherally inserted central venous catheter complications in children. JAMA Pediatr 2013; 167:429-435.
40. Centers for Disease Control and Prevention. Central Line-Associated Bloodstream Infection (CLABSI) Event. http://www.cdc.gov.nhsn.PDFs/pscManual/ 4PSC-CLABScurrent.pdf Accessed 28 February 2014.
41. Shrestha NK, Bhaskaran A, Scalera NM, et al. Antimicrobial stewardship at transition of care from hospital to community. Infect Control Hosp Epidemiol 2012; 33:401-404.
42. Sharma R, Loomis W, Brown RB. Impact of mandatory inpatient infectious disease consultation on outpatient parenteral antibiotic therapy. Am J Med Sci 2005; 330:60-64.
43. Shrestha NK, Bhaskaran A, Scalera NM, et al. Contribution of infectious disease consultation toward the care of inpatients being considered for community-based parenteral antiinfective therapy. J Hosp Med 2012; 7: 365-369.
44. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166:2138-2144.
45. Mohr JF, Murray BE. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007; 44:1536-1542.
46. Benner KW, Worthington MA, Kimberlin DW, et al. Correlation of vancomycin dosing to serum concentrations in pediatric patients: a retrospective database review. J Pediatr Pharmacol Ther 2009; 14:86-93.
47. Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J 2009; 28:398-402.
48. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin PharmacokinetV 43 2004; 925-942.
49. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66:82-98.
50. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011; 52:975-981.
51. McKamy S, Hernandez E, Jahng M, et al. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr 2011; 158:422-426.
52. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25:679-687.
53. Jeffres MN, Isakow W, Doherty JA, et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with healthcare-Associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007; 29:1107-1115.
54. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 52:1330-1336.
55. Bond CA, Raehl CL. Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapy. Am J Health Syst Pharm 2005; 62:1596-1605.
56. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135:1924-1934; 1934 e1921-1924.
57. Wallace WC, Cinat M, Gornick WB, et al. Nosocomial infections in the surgical intensive care unit: a difference between trauma and surgical patients. Am SurgV 65 1999; 987-990.
58. Delgado-Rodriguez M, Sillero-Arenas M, Medina-Cuadros M, Martinez-Gallego G. Nosocomial infections in surgical patients: comparison of two measures of intrinsic patient risk. Infect Control Hosp Epidemiol 1997; 18:19-23.
59. Horan TC, Culver DH, Gaynes RP, et al. Nosocomial infections in surgical patients in the United States, January1986-June 1992. National Nosocomial Infections Surveillance (NNIS) System. Infect Control Hosp Epidemiol 1993; 14:73-80.
60. Wong LS, Kaukuntla HK, Lam FT, Fraser IA. A survey of patient satisfaction after day case surgery. Int J Clin Pract 1999; 53:189-191.
61. Mangram AJ, Horan TC, Pearson ML, et al. Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control 1999; 27:97-132; quiz 133-134; discussion 96.
62. Kirkland KB, Briggs JP, Trivette SL, et al. The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. Infect Control Hosp Epidemiol 1999; 20:725-730.
63. Classen DC, Evans RS, Pestotnik SL, et al. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J MedV 326 1992; 281-286.
64. DiPiro JT, Vallner JJ, Bowden TA Jr, et al. Intraoperative serum and tissue activity of cefazolin and cefoxitin. Arch SurgV 120 1985; 829-832.
65. Polk HC Jr, Lopez-Mayor JF. Postoperative wound infection: a prospective study of determinant factors and prevention. Surgery 1969; 66:97-103.
66. Polk HC Jr, Trachtenberg L, Finn MP. Antibiotic activity in surgical incisions. The basis of prophylaxis in selected operations. JAMA 1980; 244:1353-1354.
67. Stone HH, Hooper CA, Kolb LD, et al. Antibiotic prophylaxis in gastric, biliary and colonic surgery. Ann Surg 1976; 184:443-452.
68. Burke JF. The effective period of preventive antibiotic action in experimental incisions and dermal lesions. Surgery 1961; 50:161-168.
69. Miles AA, Miles EM, Burke J. The value and duration of defence reactions of the skin to the primary lodgement of bacteria. Br J Exp PatholV 38 1957; 79-96.
70. Matuschka PR, Cheadle WG, Burke JD, Garrison RN. A new standard of care: administration of preoperative antibiotics in the operating room. Am Surg 1997; 63:500-503.
71. Gorecki P, Schein M, Rucinski JC, Wise L. Antibiotic administration in patients undergoing common surgical procedures in a community teaching hospital: the chaos continues. World J Surg 1999; 23:429-432; discussion 433.
72. Charneski L, DeshpandeG, Smith SW. Impact of an antimicrobial allergy label in the medical record on clinical outcomes in hospitalized patients. Pharmacotherapy 2011; 31:742-747.
73. Unger NR, Gauthier TP, Cheung LW. Penicillin skin testing: potential implications for antimicrobial stewardship. Pharmacotherapy 2013; 33:856-867.